Zhejiang Hisun Pharmaceutical has received FDA approval for its ANDA 204077, a pivotal move that sets the stage for commercial entry into the U.S. market with significant potential to increase market share and revenue once manufacturing scaling is complete. This regulatory milestone positions the manufacturer favorably within the generics sector, leveraging its established production capabilities to capture value from the competitive pharmaceutical landscape.